Background
Gestational diabetes mellitus (GDM) is a disease that is characterized by glucose intolerance with onset during the pregnancy and which attenuates after delivery [
1]. Generally, 5% of all pregnancies are complicated by GDM [
2], adversely affecting the intrauterine environment, which may in turn lead to congenital abnormalities and even spontaneous abortions [
3]. Postpartum complications include a 7.5-fold increased risk at type 2 diabetes mellitus (T2DM) for the mothers [
4] and a higher risk at obesity [
5] and diabetes mellitus [
5] for the offspring. There are well-established GDM risk factors such as a high body mass index (BMI), a family history of diabetes, and certain ethnic backgrounds [
6]. More recently, low thyroid hormone levels during gestation have been postulated as an additional risk factor for GDM [
7,
8].
The thyroid hormones play a vital role in fetal growth and neurological development [
9]. To produce adequate quantities of these hormones, the body requires a sufficient iodine intake, which, according to the World Health Organization (WHO), corresponds to a minimum daily consumption of 250 μg of iodine for pregnant and lactating women [
10]. Iodine deficiencies in adults, assessed using urinary iodine concentrations, have been linked with altered insulin and glucose homeostasis [
11], mainly via the thyroid hormones [
7]. For example, these hormones can reduce the availability of insulin by lowering the half-life of and increasing the breakdown of insulin [
12]. Secondly, the expression of glucose transporter 2 in liver cells is increased, resulting in a higher hepatic glucose efflux [
12]. In 2013, a nation-wide study in Belgium revealed that iodine intake in women of childbearing age and those in early pregnancy have an inadequate iodine intake [
13], resulting in a mild-to-moderate iodine-deficient population. These findings were corroborated within the ongoing ENVironmental Influence
ON early AGEing (ENVIRONAGE) birth cohort [
14].
Considering the placental iodine concentration as a proxy of long-term iodine intake [
15], to our knowledge, no epidemiological studies to date have investigated the association between gestational diabetes mellitus and placental iodine load. We postulate that placental iodine concentrations are linked with the incidence of GDM. Moreover, evidence is lacking whether placental iodine could play a role in the insulin homeostasis, insulin resistance, and β-cell activity.
Research design and methods
Research design
Mother-newborn pairs were enrolled in the ENVIR
ONAGE birth cohort. The Ethics Committee of Hasselt University and East-Limburg Hospital (Genk, Belgium) approved the study protocol, which was carried out following the Declaration of Helsinki. All participating mothers were asked to provide written informed consent at the birth of their newborn in the East-Limburg Hospital. Mothers could be included in the cohort if they were able to fill out questionnaires in Dutch, did not have a planned cesarean, and provided written informed consent. Full details of the study protocol were published previously [
16].
Questionnaires were used to collect sociodemographic information such as maternal birthdate, education, smoking status, pre-pregnancy body mass index (BMI), alcohol consumption during pregnancy, newborns’ ethnicity, and parity. We coded maternal education as “low” (no diploma or primary school), “middle” (high school), and “high” (college or university degree). Smoking status was classified as “non-smokers,” “cessation before pregnancy,” and “smoked during pregnancy.” Alcoholic beverage consumption was categorized as “none” or as “maximally one glass per day.” Ethnicity was coded based on the native country of the neonate’s grandparents as either “European” (at least two grandparents were European) or “non-European” (at least three grandparents were of non-European origin). For parity, the newborns were coded as primiparous (first child), secundiparous (second child), or multiparous (third or later child).
Medical records of the hospital were used to retrieve information on maternal weight gain during pregnancy, newborns’ sex, gestational age, and medical conditions such as GDM, thyroid problems, pre-eclampsia, and hypertension. GDM was determined between the 24th and 28th week of gestation at the hospital via the “two-step” approach of the American Diabetes Association [
17]: a 50-g (non-fasting) glucose challenge test (GCT) followed by a 100-g oral glucose tolerance test (OGTT) if the GCT was positive. In short, mothers who had a glycemic value of more than 140 mg/dL or 7.8 mmol/L after 1 h during the GCT moved on to OGTT. During this test, they drank a solution containing 100 g of glucose, and the glycemic values were measured when sober (threshold 95 mg/dL or 5.3 mmol/L) and after 1 h (threshold 180 mg/dL or 10 mmol/L), 2 h (threshold 155 mg/dL or 8.6 mmol/L), and 3 h (threshold 140 mg/dL or 7.8 mmol/L). If at least two measurements were above the thresholds, the mother-to-be was diagnosed with GDM.
Blood sampling, biochemical measurements, and HOMA-IR determination
We collected cord blood immediately after delivery in an 8 mL plastic BD Vacutainer© Lithium Heparin tubes (BD, Franklin Lakes, NJ, USA) and maternal blood one day after delivery in plastic BD Vacutainer EDTA tube (BD, Franklin Lakes, NJ, USA). Samples were centrifuged at 2500g for 15 min, and the obtained plasma was frozen at − 80 °C. The clinical laboratory of the East-Limburg Hospital measured the plasma levels of insulin (pmol/L) and glucose (mmol/L) with an electro-chemiluminescence immunoassay using the Modular E170 automatic analyzer (Roche, Basel, Switzerland).
The insulin resistance (IR) and β-cell activity were assessed via the updated Homeostasis Model Assessment (HOMA) [
18]. This technique calculates the β-cell function and IR from basal glucose and insulin concentrations. Therefore, it is necessary to provide clinically realistic values, which are representative for fasting subjects. Thus, plasma glucose should range between 3.5 and 25.0 mmol/L and plasma insulin concentrations between 20 and 400 pmol/L [
18].
Placental tissue collection and iodine analysis
Placentas were frozen at − 20 °C within 10 min after delivery. They were minimally thawed, and biopsies were taken at three standardized locations, situated at 2 cm from the umbilical cord. We cut away any membranes and rubbed the tissue against a Grade 54 filter paper (GE Healthcare, Chicago, USA) to remove any excess of blood. The tissue samples were stored in metal-free containers (Sterile propylene tubes; VWR, PA, USA) and were frozen at − 20 °C until iodine determination. For each placenta, equal amounts of the biopsies were pooled from each of the three sampling locations to obtain 500 mg of tissue that was placed in a 0.5% tetramethylammonium hydroxide (TMAH) solution and heated to 90 °C for 3 h in a DigiPREP block digestion system (SCP SCIENCE, Quebec, Canada). Iodine was measured via ICP-MS on an Elan DRC II (Perkin Elmer, MA, USA) on mass
127I, with
125Te as an internal standard. A more detailed description of the method is provided by Neven and colleagues [
14].
Statistical methods
Database management and statistical analysis were performed with the SAS software, version 9.4 (SAS Institute, Cary, NC, USA). Mean ± standard deviation (SD) is given for continuous variables and the proportion for categorical variables. The normality of the data distributions was tested with the Shapiro-Wilk statistic and quantile-quantile plots. To study the possible confounding structure in our data set, we assessed the distributions of continuous variables (ANOVA) and the proportions of categorical variables (χ2-statistics) across tertiles of the placental iodine concentrations.
In the first analysis, we assumed that placental iodine concentrations were causally linked to the likelihood of developing GDM. Therefore, we used a multivariate logistic regression model to evaluate the relationship between placental iodine load and the incidence of GDM. We accounted for the following a priori chosen variables based on previous findings [
19]: maternal education, hypertension, smoking status, pre-pregnancy BMI, maternal age at delivery, gestational weight gain, alcohol use, neonatal parity, gestational age, ethnicity, and sex of the neonate. Correction for these variables was done in all the subsequent analyses as well. The results are presented as odds ratios (ORs) with the 95% confidence intervals (95%CI). To assess the public health significance of the GDM findings, we calculated the population attributable fraction (PAF) [
20] for the total population and by contrasting the first versus the third tertile of placental iodine load.
In a second analysis, a generalized linear model was used to investigate the relationship of the maternal and cord plasma concentrations of insulin (collected at one day after delivery and at delivery, respectively) with the placental iodine concentrations in non-GDM mothers. In a sensitivity analysis, we included the GDM mothers (n = 12). Because the plasma insulin concentrations needed log-transformation to ensure normality, we presented these results as a percent change for a 5 μg/kg increment in placental iodine.
The HOMA-IR method [
18] was used in a third analysis to assess the insulin resistance and β-cell activity in a healthy subset (i.e., excluding mothers with hypertension and/or GDM). We used a mathematical model of fasting plasma glucose and insulin concentrations to estimate insulin sensitivity.
Role of the funding source
The funder of the study had no role in the study design, data collection, data analysis, data interpretation, or writing the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Discussion
Iodine deficiencies have been linked with a multitude of adverse health outcomes such as lower IQ points in children [
21], attention deficit and hyperactivity disorders [
22], and hypothyroidism [
10]. The current study adds some key findings to this list: (1) a lower placental iodine load was linked with a higher risk at GDM, and, assuming for causality, over half of the GDM incidence could have been prevented if placental iodine levels of women from the lowest tertile would have been that of the highest tertile; (2) in neonates, the insulin concentration in cord plasma was inversely associated with placental iodine load; and 3) in both maternal and cord plasma, the HOMA-IR index and β-cell activity were negatively associated with placental iodine load, albeit with a borderline statistical significance.
In the literature on the risk at GDM, the relative importance of iodine sufficiency is still debated. A recent longitudinal case-control study investigated the association of FT
3, FT
4, and the FT
3/FT
4 ratio with GDM. The authors observed that FT
4 concentrations were significantly lower in GDM cases in the first and second trimesters compared to non-GDM controls. At the same time, FT
3 and the FT
3/FT
4 ratio was higher in women with GDM. Another prospective cohort of 27,513 pregnant women showed that lower levels of free thyroxine in early pregnancy (i.e., 9 to 14 weeks) were a risk factor for GDM incidence, as assessed at weeks 24 to 28 of gestation [
7].
In contrast, a Finnish birth cohort found that lower maternal plasma iodine levels in the first trimester of pregnancy were not associated with risk at GDM [
23]. However, it should be noted that Bell and colleagues [
23] measured iodine in blood plasma, which reflects only the circulating levels of iodine and would, therefore, be a better proxy of thyroid function than iodine status [
24,
25]. Their findings are in contrast to the placental iodine load, which mainly reflects the long-term gestational iodine status of women and hence would be more representative for the iodine status among pregnant women [
14,
15]. Assuming for causality, our findings provide evidence of a higher incidence of GDM when placental iodine concentrations were in the lower range (PAF = 0.4). This is in agreement with observations made by Charoenratana et al. [
26], as they observed that women in Thailand who were deficient in iodine (measured in urine) during pregnancy had a higher prevalence of GDM compared to iodine-replete women. Interestingly, the Belgian population [
13] aligns more with the latter study in terms of gestational iodine deficiency, compared to the Finnish people, whom have lower rates of gestational iodine deficiencies [
27]. Although the current evidence seems inconclusive, our findings highlight a possible link between GDM and long-term gestational iodine deficiency.
It is thus plausible that a functional link exists between the iodine status and the onset of diabetes. This link could be traced back to insulin, as it recently became apparent that iodine deficiencies and insulin resistance are tightly related [
28]. Several studies pointed out that urinary iodine concentrations were lower in people diagnosed with T2DM compared to the control groups and that the urinary iodine concentrations were inversely linked with the plasma insulin levels and the HOMA-IR index [
11,
28,
29]. Although these studies concerning T2DM, GDM and T2DM share a similar pathophysiology: insulin resistance accompanied by a pancreatic β-cell insufficiency [
30]. Along similar lines, we showed that placental iodine inversely associated with the insulin concentrations, the HOMA-IR index, and the β-cell activity at birth. We could still postulate that a mild-to-moderate iodine deficiency is linked with subclinical and early-onset changes in the insulin homeostasis in healthy pregnant women. Recently, it has been suggested that inflammatory cytokines, secreted by adipose tissue of insulin-resistant patients, and hyperinsulinemia itself could negatively modulate the expression of the sodium/iodide symporter on the apical surface of enterocytes, thus inducing a decrease in iodine absorption [
28,
31]. This implies a functional association (possibly a negative feedback loop) between insulin resistance and iodine deficiency.
Although the exact mechanism is still unclear, it could be postulated that iodine deficiencies lead to an altered thyroid hormone homeostasis and a dysregulation of glucose metabolism [
7]. In rodent studies, Kemp and colleagues [
12] observed that the glucose transporter 2 expression in the rats' liver, which plays a significant role in maintaining average blood glucose concentrations, was influenced by the thyroid status. Hence, it is possible that an altered thyroid status contributes to an altered hepatic glucose turnover [
12]. Another postulated mechanism is that during hyperthyroidism, the half-life of insulin is reduced, the degradation of insulin is heightened, and biologically inactive proinsulin is released [
32]. Contrastingly, during hypothyroidism, liver glucose production is decreased [
32], which is in line with Kemp et al. [
12]. This would lead to lower insulin requirements in diabetic, hypothyroid patients. Another potential mechanism could be investigated via the triage theory of Bruce Ames [
33]. According to this theory, episodic shortages in micronutrients are handled in a triage-like allocation mechanism, which prefers short-term “survival” over long-term adverse health effects. Because iodine is involved in various pathways, it is possible that the allocation mechanism could prefer the use of iodine in only a select number of structurally important pathways. For example, the use of iodine in the thyroid hormone production could be a preferred pathway over the use of iodine as an antioxidant agent. Iodine deficiencies have been linked to increased amounts of oxidative stress and a lower antioxidant capacity in pregnant women [
34]. Interestingly, women with GDM had a higher presence of oxidative stress in the placenta compared to healthy controls [
35]. It could prove informative to investigate a broader range of iodine-associated pathways at the same time in order to examine the effect of mild-to-moderate iodine deficiency thoroughly.
Strengths and limitations
Our study has several strengths: Firstly, compared to other studies that used urinary iodine concentrations to estimate gestational iodine status, we used the placental iodine load as a marker for long-term gestational iodine accumulation. This biomarker proves to be more reliable and accurate compared to the short-term feature of urinary iodine concentrations [
14,
15]. Secondly, the diagnosis of GDM was assessed by using the clinical biomarkers (i.e. GCT and OGTT) and performed by physicians from the recruitment hospital according to the American Diabetes Association guidelines [
17]. Thirdly, our findings are generalizable to the Belgian gestational population (Additional file
2: Table S2).
We acknowledge some potential limitations. Because we used placental iodine concentrations of term-born children, no dynamic time-dependent iodine concentrations could be determined. The number of women diagnosed with GDM in the current study is low (
n = 20; 4.3%). Nevertheless, this incidence of GDM is generally found for normal populations [
2]. Moreover, our PAF calculation estimated that over 50% of the GDM cases could be prevented, which is in line with findings from a meta-analysis by Toulis and colleagues [
8], who provided evidence that the risk at GDM increased by 50% in women with subclinical hypothyroidism. Given the observational study design, we cannot infer a causal link between placental iodine load and GDM. Even though previous findings indicated that an altered thyroid hormone status is more likely to cause GDM, it is still possible for GDM to affect thyroid hormones. For example, in diabetic patients, the thyroid-stimulating hormone response to the thyrotropin-releasing hormone is impaired [
32]. Moreover, the peripheral conversion from thyroxine to triiodothyronine in diabetics could be impaired as well [
32].
Conclusions
Gestational iodine intake is essential as it provides a healthy intrauterine environment for optimal fetal growth. The current study sheds some light on the link between placental iodine load and the heightened risk at GDM, as well as an association with altered plasma insulin concentration, HOMA-IR index, and β-cell activity. The specific mechanisms of how the iodine status, prior to, and during gestation could heighten the risk at GDM remains to be unraveled. Nevertheless, our findings on GDM and placental iodine may help to improve the understanding of the developmental origins of health and disease. Our study coveys an important public health message, in that maintaining an adequate iodine status in the population at large may avert a significant portion of gestational diabetes mellitus and adverse health effects later in the neonates’ life.
Clinicians and healthcare managers should keep in mind that combatting iodine deficiency is complex and needs careful planning, even before pregnancy. Current evidence suggests that starting iodine supplementation during gestation might not be the most effective method to optimize the iodine supply to the mother and fetus [
36].
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.